VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AORT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AORTArtivion, Inc.
$18.54$900M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. AORT
  4. Financial Ratios

Artivion, Inc. (AORT) Financial Ratios

Latest Ratios: P/E Ratio -51.3x · EV/EBITDA 31.8x · ROE 2.7%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

AORT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$900M$2.2B$1.2B$728M$485M$793M$894M$1.0B$1.0B$654M$629M
Enterprise Value$1.1B$2.4B$1.5B$1.0B$803M$1.1B$1.1B$1.2B$1.2B$840M$643M
P/E Ratio →-51.34217.19—————600.67—174.0959.84
P/S Ratio1.874.873.072.061.552.653.533.713.933.453.48
P/B Ratio1.954.804.312.591.712.642.723.593.762.343.01
P/FCF——107.8563.93——177.33132.25252.35173.9051.12
P/OCF23.6056.4153.5938.70——72.2764.80104.5860.5631.87

P/E links to full P/E history page with 30-year chart

AORT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—5.393.862.902.563.684.544.484.624.433.56
EV / EBITDA31.8048.3323.7835.6728.0234.2837.9534.9844.3547.4121.28
EV / EBIT42.1457.5056.06276.83247.74534.14—74.83100.3599.4938.02
EV / FCF——135.8090.20——228.10159.51296.81223.2552.28

AORT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin61.3%61.3%64.0%64.7%64.5%66.1%66.3%66.3%65.8%67.8%65.9%
Operating Margin6.1%6.1%10.0%1.6%2.0%2.7%1.0%6.2%3.5%4.2%12.1%
Net Profit Margin2.2%2.2%-3.4%-8.7%-6.1%-5.0%-6.6%0.6%-1.4%2.0%6.0%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE2.7%2.7%-4.8%-10.8%-6.6%-4.7%-5.4%0.6%-1.4%1.5%5.9%
ROA1.2%1.2%-1.7%-3.9%-2.5%-1.9%-2.4%0.3%-0.7%0.8%4.3%
ROIC3.2%3.2%5.0%0.7%0.8%1.0%0.3%2.7%1.5%1.7%9.8%
ROCE3.6%3.6%5.3%0.8%0.8%1.1%0.4%3.1%1.7%1.9%9.7%

AORT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.650.651.311.271.251.200.970.860.810.810.34
Debt / EBITDA5.945.945.7412.4312.4611.2810.486.938.1612.782.37
Net Debt / Equity—0.511.121.061.121.020.780.740.660.670.07
Net Debt / EBITDA4.624.624.9010.3911.089.578.455.986.6410.480.47
Debt / FCF——27.9526.27——50.7827.2644.4649.341.16
Interest Coverage1.561.560.780.150.180.12-0.031.110.771.735.56

AORT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.992.994.344.854.985.513.884.155.194.184.89
Quick Ratio2.082.083.153.433.483.802.672.973.873.094.02
Cash Ratio0.640.640.801.020.791.221.020.751.200.951.90
Asset Turnover—0.500.490.450.410.380.320.460.460.320.57
Inventory Turnover1.851.851.751.521.491.321.171.761.981.312.34
Days Sales Outstanding—85.7580.6976.4480.9470.9770.2773.8171.4298.9860.90

AORT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield—0.5%—————0.2%—0.6%1.7%
FCF Yield——0.9%1.6%——0.6%0.8%0.4%0.6%2.0%
Buyback Yield0.0%0.0%0.0%0.1%0.4%0.2%0.2%0.3%0.2%0.2%0.1%
Total Shareholder Yield0.0%0.0%0.0%0.1%0.4%0.2%0.2%0.3%0.2%0.2%0.1%
Shares Outstanding—$47M$42M$41M$40M$39M$38M$38M$36M$34M$33M

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Earnings miss and cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Priced Against Thin Earnings

Based on reported figures, Artivion trades at 34.09x trailing EV/EBITDA and 2.04x sales, a premium that the 2.2% net margin and negative trailing P/E of -55.97 do not clearly justify on current earnings.

Traditional earnings multiples are not meaningful here because net income is negative, so the market is effectively anchoring on EV/EBITDA and sales. The 34x EBITDA multiple sits well above the medical device peer group, with AtriCure at 73.9x the only peer with a higher multiple and TransMedics near 23.9x, suggesting investors are paying for the U.S. stent-graft platform expansion rather than current cash earnings. This pricing appears to depend on successful JOTEC portfolio approvals, and investors should monitor whether the multiple compresses if that timeline slips.

Operating Margin Compression Erodes Earning Power

As reported in quarterly statements, Artivion's operating margin fell from 11.1% in 2025Q3 to 2.4% in 2026Q3, while gross margin compressed roughly 420 basis points to 61.4% over the same span.

Gross margin has held within a 60% to 66% band, so the deterioration is concentrated below the gross line, where SG&A absorbed roughly half of revenue in the latest quarter. This suggests the earnings problem is one of operating cost structure rather than pricing or product mix alone. The gap between a 2.4% operating margin and a -6.4% net margin indicates below-the-line items are also weighing on reported profit, warranting investigation of the specific drivers.

Returns Near Zero With Goodwill Weighing

Based on Artivion's reported figures, ROIC stood at 0.3% in 2026Q3 and ROE at -1.8%, far below the 18.8% ROIC and 28.4% ROE reported by TransMedics, indicating little value creation on invested capital.

Returns on capital have been low across the ten-quarter window, peaking at only 1.5% ROIC in 2025Q3, which is weak for a device company with high gross margins. Goodwill of roughly $345M from acquisitions sits inside the invested capital base, so the low ROIC may reflect acquisition premiums not yet translating into operating profit. Investors should evaluate whether the JOTEC-related capital deployment can lift returns toward a level justifying the current enterprise value.

Debt Rebuild Reverses Deleveraging Progress

According to reported balance sheets, total debt rose from $258.2M in 2026Q1 to $407.0M in 2026Q3, lifting debt-to-equity to 0.91 while interest coverage fell to 0.31x, signaling weaker debt service comfort.

Coverage of 0.31x means operating earnings in 2026Q3 covered only about a third of interest expense, a level that merits close monitoring regardless of the still-moderate debt-to-equity ratio. The reversal of the earlier debt paydown suggests renewed borrowing, which may reflect funding needs from negative free cash flow. Refinancing terms and covenant headroom are not disclosed in the supplied data, so their risk cannot be assessed here.

Strong Current Ratio Masks Thin Cash Position

Based on reported figures, the 4.42 current ratio and 3.02 quick ratio in 2026Q3 look comfortable, yet cash of $48.4M against $407.0M of total debt suggests limited cash cushion for servicing obligations.

The high current ratio is supported largely by receivables and inventory rather than cash, so the quick ratio of 3.02 remains strong but depends on collection of an 81-day DSO. Inventory is tied up for roughly 202 days, meaning a stress scenario in which collections slow could quickly erode working capital flexibility. The liquidity cushion therefore appears adequate on paper but may be less resilient than the ratios imply under severe stress.

Long Cash Cycle Ties Up Working Capital

As reported in quarterly figures, Artivion's cash conversion cycle reached 246 days in 2026Q3, with inventory days of 202 far exceeding the 37-day DPO, leaving substantial working capital absorbed by inventory.

A cash conversion cycle near 250 days is structurally long, driven primarily by slow-turning inventory typical of preservation and implant businesses. The thin payables cushion means the company funds most of its operations rather than leaning on suppliers. Working capital drains noted in cash flow results are consistent with this inventory build, suggesting efficiency improvement would be a key lever for cash generation.

Reported Equity Growth May Overstate Balance Sheet Strength

Based on reported figures, the 0.91 debt-to-equity ratio looks moderate, but negative retained earnings and a 39.6x EBITDA leverage reading suggest headline equity strength may understate the underlying debt burden.

The apparent deleveraging from 1.31 to 0.91 debt-to-equity may reflect capital injections rather than earnings-driven strength, since retained earnings remain negative. Measured against EBITDA rather than book equity, leverage appears considerably higher, which investors may wish to weigh alongside the 0.31x interest coverage. This suggests the balance sheet could be less resilient than headline ratios imply, warranting further investigation of the debt maturity profile.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open AORT Terminal

AORT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AORT — Frequently Asked Questions

Quick answers to the most common questions about buying AORT stock.

What is Artivion, Inc.'s P/E ratio?

Artivion, Inc.'s current P/E ratio is -51.3x. The historical average is 60.0x.

What is Artivion, Inc.'s EV/EBITDA?

Artivion, Inc.'s current EV/EBITDA is 31.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 30.8x.

What is Artivion, Inc.'s ROE?

Artivion, Inc.'s return on equity (ROE) is 2.7%. The historical average is -0.4%.

Is AORT stock overvalued?

Based on historical data, Artivion, Inc. is trading at a P/E of -51.3x. Compare with industry peers and growth rates for a complete picture.

What are Artivion, Inc.'s profit margins?

Artivion, Inc. has 61.3% gross margin and 6.1% operating margin.

How much debt does Artivion, Inc. have?

Artivion, Inc.'s Debt/EBITDA ratio is 5.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.